It’s another pipeline setback for GSK, which announced last week that its big gamble on a cancer drug developed by Germany’s Merck KGaA looks unlikely to pay out. Darmstadt-based Merck said ...

Shares in pharmaceutical company GlaxoSmithKline (GSK ... another major US pharmaceutical company, and Germany-based ...

The €150 million collaboration between UK pharma GSK and Germany’s CureVac builds on their existing relationship and will jointly develop next generation mRNA vaccines. It will attempt to ...

The European stock markets closed lower in Monday trading as The Stoxx Europe fell 0.55%, Germany's DAX lost 0.41 ... And in corporate news, GSK said Monday that it has agreed to acquire oncology ...

GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix ...

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...